Tazobactam and Piperacillin API By Type (18,14), By Application (Injection, Others), and Region Forecast 2019-2030

Tazobactam and Piperacillin API Market Dynamics

Bacterial diseases continue to be the leading cause of morbidity and mortality worldwide. Inadequate funding, subpar microbiology services, a lack of technical experts, and a need for epidemiological data to guide better preventive and treatment strategies all contribute to the rise in the burden of bacterial infections. Infectious diseases are prevalent in different parts of the world, regardless of developing or developed countries, and are heavily influenced by vulnerable populations, social inequality, economic imbalance, limited access to healthcare, and other factors. A high incidence of antimicrobial resistance (AMR) also coexists with this rise in the burden of bacterial illnesses.The global burden of infectious diseases is high, particularly in low- and lower-middle-income countries (LMICs). In contrast, non-communicable diseases are responsible for most deaths in upper-middle and high-income countries.

However, developed countries are still vulnerable to outbreaks of bacterial infections due to increased international travel. In 2019, approximately 7 million people died of infectious diseases, accounting for nearly 12% of all deaths globally. Furthermore, it has been estimated that 700,000 deaths occur each year globally due to drug-resistant organisms. If preventive and control measures are not taken, this number could rise to 10 million by 2050, with an economic loss of $100 trillion.Piperacillin/tazobactam is an effective combination antibiotic against a broad range of bacteria, including those that produce beta-lactamases. It is used to treat various infections, including lower respiratory tract infections, intra-abdominal infections, urinary tract infections, gynecological infections, skin and soft tissue infections, and fever in patients with neutropenia. In severe cases, piperacillin/tazobactam may be combined with an aminoglycoside antibiotic. Moreover, the demand for piperacillin/tazobactam API is increasing due to the increase in prevalence of infectious diseases.